Acura Pharmaceuticals

Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse. As of 2012, the company had several opioid products under development, which would use "Aversion Technology".[2] As of 2014, the company was a publicly traded company, listed on NASDAQ under the symbol "ACUR".

Acura Pharmaceuticals Inc.
TypePublic
NASDAQ: ACUR
IndustryPharmaceutical industry
Founded1935[general 1]:3
HeadquartersPalatine, Illinois
ProductsPharmaceuticals
Revenue US$ .75 million (2015)[1]
Websiteacurapharm.com

History

In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.[3]

Technologies

Aversion Technology

Aversion Technology, provides abuse deterrent benefits to orally administered pharmaceutical drugs.[4][5] Many of the products approved by the US Food and Drug Administration, such as OXECTA from Pfizer, have incorporated such technology.

Impede Technology

Impede Technology is used in easily dissolved tablets and involves the addition of an inactive ingredient polymer matrix, which has been shown to form a thick gel and start a conversion process of crushed pseudoephedrine (PSE).[6] This technology the aims of the Combat Methamphetamine Epidemic Act enacted in the United States in 2006.[7]

Corporate affairs

License agreements

The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.[8]

Product adoptions

In 2013, multiple retailers – including Kroger and Fruth Pharmacy – stocked Acura's product Nexafed, which is a drug that attempts to prevent illicit methamphetamine synthesis by incorporating the new pseudoephedrine conversion technology from the company.[9] Nexafed has blocker in it that stops the making of methamphetamine.

References
  1. "Acura Pharmaceuticals Financial Statements". United States Securities and Exchange Commission.
  2. "Acura Pharmaceuticals, Inc". Google Finance. Google. 266634. Retrieved February 15, 2014.
  3. "Acura Pharmaceuticals Inc Announces Settlement of Oxecta Patent Litigation With Par Pharmaceutical and Impax Laboratories Inc". Reuters. Reuters. October 9, 2013. Archived from the original on February 15, 2014.
  4. "Acura Pharmaceuticals, Inc. (ACUR) Announces Termination of AVERSION License Agreement With Pfizer Inc. (PFE)". BioSpace. Dice Holdings. September 27, 2012. Archived from the original on November 8, 2012. Retrieved February 15, 2014.
  5. "Acura Pharmaceuticals Announces Earlier Return of Development Products" (Press release). Acura Pharmaceuticals. September 26, 2012. Archived from the original on December 16, 2012. Retrieved February 15, 2014.
  6. "How Impede Technology Works". Nexafed. Acura Pharmaceuticals. Archived from the original on February 15, 2014. Retrieved February 15, 2014.
  7. "IMPEDE® Technology". Acura Pharmaceuticals. Archived from the original on December 18, 2013. Retrieved February 15, 2014.
  8. https://finance.yahoo.com/q/pr?s=ACUR+Profile
  9. Olsavsky, Rebecca (February 4, 2014). "Kroger stocks meth-resistant drug". Herald-Star. Archived from the original on February 15, 2014. Retrieved February 15, 2014.

General references
  1. "ACURA PHARMACEUTICALS, INC" (PDF). EDGAR Online. Form 10-K, 1996. Acura Pharmaceuticals. March 31, 1997. Retrieved February 15, 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.